Please assess the completion status of the following clinical trial:

Trial Title: Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Patient with PBC defined by 2 in 3 of the following criteria: a.Positive antimitochondrial antibody type M2; b.Abnormal serum alkaline phosphatases (ALP \> 1,5N) and aminotransferase (AST/ALT \> 1N) activities; c.Histological hepatic injuries consistent with PBC.~Exclusion Criteria:~1. Pregnancy or desire of pregnancy.~2. Breast-feeding.~3. Co-existing liver diseases such as acute or chronic viral hepatitis, alcoholic liver disease, choledocholithiasis, autoimmune hepatitis, biopsy-proven non-alcoholic fatty liver disease, Wilson's disease and hemochromatosis~4. History or presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy, or poorly controlled ascites).~5. History of urolithiasis, nephritis or renal failure (clearance of creatinine \< 60 ml/mn).~6. Hepatotoxic drugs use before recruiting.~7. Fenofibrate anaphylaxis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fenofibrate + UDCA (Type: EXPERIMENTAL): Fenofibrate (200 mg/day) in combination with ursodeoxycholic acid (13-15 mg/kg/day)
- Monotherapy (Type: ACTIVE_COMPARATOR): UDCA 13-15mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).